Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).

Trial Details

NCT ID
NCT03832361
Phase
PHASE2
Sponsor
Alessandro Santin
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • IMGN853
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • Radiologically confirmed (ie, CT scan and/or MRI) persistent or recurrent endometrial cancer
  • Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Uterine serous carcinoma (Pure or Mixed), Gr…
  • Have measurable disease
  • FRα-positive tumor expression as defined in the protocol

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →